Skip to content
OpenCapital
Get started

Integra LifeSciences IART Securitization program outstanding borrowings, maximum limit

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept iart:TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's securitization program outstanding borrowings, maximum limit.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's securitization program outstanding borrowings, maximum limit?
Integra LifeSciences (IART) reported securitization program outstanding borrowings, maximum limit of $150M in Q1 2026.
How has Integra LifeSciences's securitization program outstanding borrowings, maximum limit changed year-over-year?
Integra LifeSciences's securitization program outstanding borrowings, maximum limit decreased by 0.0% year-over-year, from $150M to $150M.